A phase1 study to demonstrate \[68Ga\]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
14
Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Time course of uptake of [68Ga]P15-041 in bone metastases
kinetics of \[68Ga\]P15-041 uptake in known or suspected bone metastases in prostate cancer
Time frame: 60 minutes post injection
Time course of whole body distribution of [68Ga]P15-041
whole body distribution of \[68Ga\]P15-041 used for human dosimetry determination
Time frame: 3 hours post injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.